Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 result for naltrexone with bupropion

  1. Naltrexone–bupropion for managing overweight and obesity (TA494)

    Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.

    Technology appraisal guidance
    Published
    12 December 2017
    View recommendations

    Sections for TA494